Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517722 | 1.00 | CSNK1A1 (0.50) | CSNK1A1TYRO3DYRK1BBCAT2PDPK1 | |
| Hydrochloric Acid SCHEMBL30810223 | 0.98 | CSNK1A1 (0.49) | CSNK1A1TYRO3DYRK1BBCAT2PDPK1 | |
| SCHEMBL918767 | 0.94 | CSNK1A1 (0.48) | CSNK1A1TYRO3DYRK1BBCAT2PDPK1 | |
| Pyrrole SCHEMBL11072397 | 0.91 | CSNK1A1 (0.50) | CSNK1A1TYRO3DYRK1BBCAT2PDPK1 | |
| SCHEMBL919208 | 0.90 | CSNK1A1 (0.44) | CSNK1A1TYRO3DYRK1BBCAT2PDPK1 | |
| Nitrobenzene SCHEMBL27714783 | 0.87 | MAPT (0.43) | CSNK1A1TYRO3DYRK1BBCAT2PDPK1 | |
| SCHEMBL27744970 | 0.86 | TYK2 (0.41) | CSNK1A1TYRO3DYRK1BBCAT2PDPK1 | |
| SCHEMBL27599253 | 0.86 | TYK2 (0.41) | CSNK1A1TYRO3DYRK1BBCAT2PDPK1 | |
| SCHEMBL5698661 | 0.85 | CYP1A2 (0.53) | PDPK1ADORA2AADORA1ALDH1A1NPC1 | |
| SCHEMBL2733045 | 0.84 | TYK2 (0.43) | CSNK1A1TYRO3DYRK1BPDPK1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058701-A | Thioether structure-containing targeted PHGDH active molecular probe, preparation method and application thereof | 中国药科大学 | 2025-05-30 | — | — | CN | claimed |
| CN-108602827-A | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | 安塞塔制药公司 | 2018-09-28 | — | — | CN | claimed |
| EP-3256449-A2 | SODIUM CHANNEL BLOCKERS | Daewoong Pharmaceutical Co., Ltd. (KR) | 2017-12-20 | — | — | EP | claimed |
| WO-2016129933-A2 | SODIUM CHANNEL BLOCKERS | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-18 | — | — | WO | claimed |
| WO-2016004305-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | claimed |
| EP-2925322-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2015-10-07 | — | — | EP | claimed |
| CN-103930409-A | Aromatic amidothiazoles, cosmetic or dermatological preparations containing said aromatic amidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin | BEIERSDORF AG | 2014-07-16 | — | — | CN | claimed |
| WO-2014085210-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-06-05 | — | — | WO | claimed |
| CN-103070876-A | Composition for resisting Japanese encephalitis virus infection and application thereof | SHANGHAI VETERINARY RES INST CAAS | 2013-05-01 | — | — | CN | claimed |
| EP-2459554-A2 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | Cadila Healthcare Limited (IN) | 2012-06-06 | — | — | EP | claimed |
| EP-2445908-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | Cadila Healthcare Limited (IN) | 2012-05-02 | — | — | EP | claimed |
| CN-102335171-A | Application of N-(2-thiazole)benzamide derivatives | SHANGHAI VETERINARY RES INST CAAS | 2012-02-01 | — | — | CN | claimed |
| WO-2011013141-A2 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2011-02-03 | — | — | WO | claimed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | claimed |
| WO-2010150280-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-29 | — | — | WO | claimed |
| EP-2086964-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | Astra Zeneca AB (SE) | 2009-08-12 | — | — | EP | claimed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | claimed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | claimed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | claimed |
| EP-4583870-A2 | MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | Mito Biopharma, LLC (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-120058701-A | Thioether structure-containing targeted PHGDH active molecular probe, preparation method and application thereof | 中国药科大学 | 2025-05-30 | — | — | CN | disclosed |
| WO-2024054766-A2 | MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | MITO BIOPHARMA, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4308122-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022194779-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-09-22 | — | — | WO | disclosed |
| US-20210380546-A1 | VACCINE ADJUVANT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-09 | — | — | US | disclosed |
| CN-106632401-B | Methods and compounds for the synthesis of fused aminodihydrothiazine derivatives | 卫材R&D管理有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-110167556-A | Thio-hydantoin androgen receptor antagonist for treating cancer | 詹森药业有限公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-110023290-A | heteroaryl carboxamide compounds as RIPK2 inhibitors | 勃林格殷格翰国际有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-109640986-A | Thio-hydantoin androgen receptor antagonists for treating cancer | 詹森药业有限公司 | 2019-04-16 | — | — | CN | disclosed |
| US-10196411-B2 | Tizoxanide phosphate and alkane sulfonate and pharmaceutical applications thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2019-02-05 | — | — | US | disclosed |
| EP-3006431-B1 | TIZOXANIDE CARBAMATE AND PHARMACEUTICAL USE THEREOF | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2019-01-30 | — | — | EP | disclosed |
| CN-108938629-A | The application of 3- methyl-N- (4- Trifluoromethoxyphen-l) benzimidazole and thiazole carboxamides | 马韫韬 | 2018-12-07 | — | — | CN | disclosed |
| CN-108853098-A | The application of N- (2- furfuryl) -3- tolimidazole and thiazole carboxamides | 山东大学齐鲁医院 | 2018-11-23 | — | — | CN | disclosed |
| US-10131643-B2 | Tizoxanide carbamate and pharmaceutical use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2018-11-20 | — | — | US | disclosed |
| CN-105030797-B | The composition of a kind of anti-japanese encephalitis virus infection and its application | 中国农业科学院上海兽医研究所 | 2018-10-23 | — | — | CN | disclosed |
| CN-105030797-B | The composition of a kind of anti-japanese encephalitis virus infection and its application | 中国农业科学院上海兽医研究所 | 2018-10-23 | — | — | CN | disclosed |
| CN-108685912-A | The application of N- (the bromo- 2- methoxyphenyls of 5-) benzimidazoles and thiazole carboxamides | 山东大学 | 2018-10-23 | — | — | CN | disclosed |
| CN-108602827-A | Imidazopyrazine inhibitors of Bruton's tyrosine kinase | 安塞塔制药公司 | 2018-09-28 | — | — | CN | disclosed |
| US-20170362261-A1 | Tizoxanide Phosphate and Alkane Sulfonate and Pharmaceutical Applications Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2017-12-21 | — | — | US | disclosed |
| EP-3239160-A1 | TIZOXANIDE PHOSPHATE AND ALKANE SULFONATE AND PHARMACEUTICAL APPLICATIONS THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2017-11-01 | — | — | EP | disclosed |
| CN-106632401-A | Methods and compounds for the synthesis of fused aminodihydrothiazine derivatives | 卫材R&D管理有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20160340326-A1 | Tizoxanide Carbamate and Pharmaceutical Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2016-11-24 | — | — | US | disclosed |
| US-9447033-B2 | Potassium channel blockers | JAPAN TOBACCO INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| EP-3006431-A1 | TIZOXANIDE CARBAMATE AND PHARMACEUTICAL USE THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2016-04-13 | — | — | EP | disclosed |
| WO-2016004305-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004272-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20150259282-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-9120762-B2 | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-09-01 | — | — | US | disclosed |
| US-9073834-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| EP-2236500-B1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2014-12-24 | — | — | EP | disclosed |
| US-20140221337-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2014-08-07 | — | — | US | disclosed |
| CN-103930409-A | Aromatic amidothiazoles, cosmetic or dermatological preparations containing said aromatic amidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin | BEIERSDORF AG | 2014-07-16 | — | — | CN | disclosed |
| US-20140140953-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2014-05-22 | — | — | US | disclosed |
| US-8673901-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2014-03-18 | — | — | US | disclosed |
| US-8642637-B2 | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-02-04 | — | — | US | disclosed |
| CN-103502231-A | Methods and compounds for the synthesis of fused aminodihydrothiazine derivatives | EISAI R&D MAN CO LTD | 2014-01-08 | — | — | CN | disclosed |
| CN-102335171-B | Application of N-(2-thiazole)benzamide derivatives | SHANGHAI VETERINARY RES INST CAAS | 2013-09-11 | — | — | CN | disclosed |
| CN-101679242-B | Ethylidene hydrazine carboxamide derivatives, preparation process and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2013-07-10 | — | — | CN | disclosed |
| US-20130123507-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2013-05-16 | — | — | US | disclosed |
| CN-103070876-A | Composition for resisting Japanese encephalitis virus infection and application thereof | SHANGHAI VETERINARY RES INST CAAS | 2013-05-01 | — | — | CN | disclosed |
| US-8367710-B2 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2013-02-05 | — | — | US | disclosed |
| CN-102159217-B | Salt of bicyclo-substituted pyrazolone azo derivative, preparation method and application thereof | JIANGSU HENGRUI MEDICINE CO | 2012-10-03 | — | — | CN | disclosed |
| US-20120164102-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
| EP-2459554-A2 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | Cadila Healthcare Limited (IN) | 2012-06-06 | — | — | EP | disclosed |
| EP-2445908-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | Cadila Healthcare Limited (IN) | 2012-05-02 | — | — | EP | disclosed |
| EP-2441457-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-04-18 | — | — | EP | disclosed |
| CN-102335171-A | Application of N-(2-thiazole)benzamide derivatives | SHANGHAI VETERINARY RES INST CAAS | 2012-02-01 | — | — | CN | disclosed |
| CN-101679286-B | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO | 2011-06-08 | — | — | CN | disclosed |
| WO-2011013141-A2 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011011514-A1 | HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010150280-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-29 | — | — | WO | disclosed |
| CN-101928281-A | Bicyclo-substituted pyrazolone azo derivative, preparation method thereof and application thereof in medicaments | SHANGHAI HENGRUI PHARM CO LTD | 2010-12-29 | — | — | CN | disclosed |
| CN-101921232-A | Salt of 2-ring substituted pyrazolone azo derivatives, and preparation method and application thereof in medicaments | SHANGHAI HENGRUI PHARM CO LTD | 2010-12-22 | — | — | CN | disclosed |
| US-20100316601-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2010-12-16 | — | — | US | disclosed |
| EP-2236500-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-10-06 | — | — | EP | disclosed |
| EP-2178852-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | Romark Laboratories, L.C. (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| CN-101679242-A | Ethylene hydrazine amide derivative, preparation method and medical application thereof | SHANGHAI HENGRUI PHARM CO LTD | 2010-03-24 | — | — | CN | disclosed |
| CN-101679286-A | Bicyclic substituted pyrazolone azo derivative, preparation method thereof and application thereof in medicine | SHANGHAI HENGRUI PHARM CO LTD | 2010-03-24 | — | — | CN | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
| CN-101514179-A | Indolone hydrazine ethylidene carbonyl compound, method for preparing same and application thereof in medicine | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2009-08-26 | — | — | CN | disclosed |
| EP-2086964-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | Astra Zeneca AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| CN-101481352-A | Bicycle substituted pyrazolone azo derivative, preparation thereof and use in medicine | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2009-07-15 | — | — | CN | disclosed |
| US-20090088371-A1 | COMBINATION THERAPY WITH SYK KINASE INHIBITOR | RIGEL PHARMACEUTICALS, INC. | 2009-04-02 | — | — | US | disclosed |
| WO-2009035788-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES L.C. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009029682-A1 | COMBINATION THERAPY WITH SYK KINASE INHIBITOR | RIGEL PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| CN-100420678-C | Cyclization process for substituted benzothiazole derivatives | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | CN | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| EP-1828153-A1 | N-(2-AMINOPHENYL)-4-(5-((ETHYLAMINO)METHYL)-1,3-THIAZOL-2-YL)BENZAMIDE AND N-(2-AMINOPHENYL)-4-(5-((ISOPROPYLAMINO)METHYL)-1,3-THIAZOL-2-YL)BENZAMIDE AS HDAC INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| US-7241783-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| CN-1870996-A | N-thiazol-2-yl-benzamide derivatives | LUNDBECK & CO AS H (DK) | 2006-11-29 | — | — | CN | disclosed |
| WO-2006064246-A1 | N- (2-AMINOPHENYL) -4- (5- ((ETHYLAMINO) METHYL) 1,3-THIAZOL-2-YL) BENZAMIDE AND N- (2-AMINOPHEYNL) -4- (5- ((ISOPROPYLAMINO) METHYL) -1,3-THIAZOL-2-YL) BENZAMIDE AS HDAC INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1656373-A2 | DERIVATIVES OF 2-ACYLAMINO-4-PHENYLTHIAZOLE, PREPARATION METHOD THEREOF AND USE OF SAME AS CHEMOKINEANTAGONISTS | Sanofi-Aventis (FR) | 2006-05-17 | — | — | EP | disclosed |
| CN-1738808-A | Cyclization process for substituted benzothiazole derivatives | HOFFMANN LA ROCHE (CH) | 2006-02-22 | — | — | CN | disclosed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | disclosed |
| EP-1583752-A2 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| EP-1349613-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004096798-A2 | DERIVATIVES OF 2-ACYLAMINO-4-PHENYLTHIAZOLE, PREPARATION METHOD THEREOF AND USE OF SAME AS CHEMOKINE ANTAGONISTS | SANOFI-AVENTIS (FR) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004060879-A2 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| US-20040058990-A1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | disclosed |
| EP-1349613-A2 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-0871619-B1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMA (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6458959-B1 | VIRICIDES AND ENZYME INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| WO-2002049413-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-27 | — | — | WO | disclosed |
| US-6348477-B1 | SUBSTITUTED PHENYL THIAZOLE DERIVATIVES AS VIRICIDES | BOEHRINGER INGELHEIM(CANADA) LTD. (CA) | 2002-02-19 | — | — | US | disclosed |
| US-6057451-A | AMINOTHIAZOLE DERIVATIVES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-05-02 | — | — | US | disclosed |
| CN-1207094-A | Phenyl thiazole derivatives with anti herpes virus properties | BOEHRINGER INGELHEIM PHARMA (US) | 1999-02-03 | — | — | CN | disclosed |
| EP-0871619-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997024343-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024343-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123507-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | THPO, MPL, TEK | CSNK1A1 1147/4885TYRO3 46/4885DYRK1B 1717/4885 |
| US-10131643-B2 | Tizoxanide carbamate and pharmaceutical use thereof | CYP2C9, CA9, CYP3A7 | CSNK1A1 653/4885TYRO3 1967/4885DYRK1B 1879/4885 |
| US-20160340326-A1 | Tizoxanide Carbamate and Pharmaceutical Use Thereof | CYP2C9, CA9, CYP3A7 | CSNK1A1 653/4885TYRO3 1967/4885DYRK1B 1879/4885 |
| US-20040058990-A1 | Thrombopoietin mimetics | MPL, THPO, TEK | CSNK1A1 4766/4885TYRO3 450/4885DYRK1B 2642/4885 |
| US-20100316601-A1 | BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | THPO, MPL, TEK | CSNK1A1 1147/4885TYRO3 46/4885DYRK1B 1717/4885 |
| US-20140221337-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | CSNK1A1 1343/4885TYRO3 2812/4885DYRK1B 1758/4885 |
| US-10196411-B2 | Tizoxanide phosphate and alkane sulfonate and pharmaceutical applications thereof | TPI1, ALK, STS | CSNK1A1 856/4885TYRO3 378/4885DYRK1B 424/4885 |
| US-20100087428-A1 | Novel Potassium Channel Blockers | HCN4, SCN2B, KCNH2 | CSNK1A1 1327/4885TYRO3 592/4885DYRK1B 2320/4885 |
| US-20210380546-A1 | VACCINE ADJUVANT | IFNG, TLR9, LY96 | CSNK1A1 3541/4885TYRO3 2234/4885DYRK1B 4737/4885 |
| US-20090088371-A1 | COMBINATION THERAPY WITH SYK KINASE INHIBITOR | MPL, SYK, BTK | CSNK1A1 775/4885TYRO3 12/4885DYRK1B 259/4885 |
| US-20150259282-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | CSNK1A1 1343/4885TYRO3 2812/4885DYRK1B 1758/4885 |
| US-20140140953-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | THPO, MPL, TEK | CSNK1A1 1184/4885TYRO3 34/4885DYRK1B 1447/4885 |
| US-20170362261-A1 | Tizoxanide Phosphate and Alkane Sulfonate and Pharmaceutical Applications Thereof | TPI1, ALK, STS | CSNK1A1 856/4885TYRO3 378/4885DYRK1B 424/4885 |
| US-20120164102-A1 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF | THPO, MPL, TEK | CSNK1A1 1184/4885TYRO3 34/4885DYRK1B 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.